A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study

2021 ◽  
Author(s):  
Xin Tang ◽  
Yuan Li ◽  
Wen-lei Qian ◽  
Wei-feng Yan ◽  
Tong Pang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Lung Cancer Patients ◽  
Prognostic Analysis ◽  
Egfr T790m

scholarly journals Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

2011 ◽  
Vol 17 (5) ◽  
pp. 1160-1168 ◽  
Author(s):  
Rafael Rosell ◽  
Miguel Angel Molina ◽  
Carlota Costa ◽  
Sara Simonetti ◽  
Ana Gimenez-Capitan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Lung Cancer Patients ◽  
Brca1 Mrna ◽  
Egfr T790m

scholarly journals Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines

2021 ◽  
Author(s):  
Alessandro Dal Maso ◽  
Martina Lorenzi ◽  
Alessandra Ferro ◽  
Sara Pilotto ◽  
Fabiana Cecere ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
T790m Mutation ◽  
Lung Cancer Patients

Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter Italian observational study including consecutive Caucasian patients referred between 2014 and 2018. Results: 167 patients were included. Median progression-free survival was 9.8 months (95% CI: 8.3–13.3) for T790M+ and 6.0 months (95% CI: 4.9–7.2) for T790M- patients, respectively. Median overall survival was 20.7 months (95% CI: 18.9–28.4) for T790M+ and 10.6 months (95% CI: 8.6–23.6) for T790M- patients, respectively. The T790M mutation correlated with absence of new sites of disease. After progression, most T790M+ patients continued osimertinib, whereas most T790M- patients received a different treatment line. Conclusion: Better outcomes were shown in patients receiving osimertinib. A more limited progression pattern for T790M+ was suggested.

Sign in / Sign up

Export Citation Format

Share Document